Le Lézard
Classified in: Science and technology
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Plug to Announce 2023 Third Quarter Results


LATHAM, N.Y., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, will announce its 2023 third quarter results on Thursday, November 9, 2023.

Join the call:

The webcast can also be accessed directly from the Plug homepage (www.plugpower.com). A playback of the call will be available online for a period of time following the call.

About Plug

Plug Power is building the hydrogen economy as the leading provider of comprehensive hydrogen fuel cell (HFC) turnkey solutions. The Company's innovative technology powers electric motors with hydrogen fuel cells amid an ongoing paradigm shift in the power, energy, and transportation industries to address climate change and energy security, while providing efficiency gains and meeting sustainability goals. Plug Power created the first commercially viable market for hydrogen fuel cell (HFC) technology. As a result, the Company has deployed over 60,000 fuel cell systems for e-mobility, more than anyone else in the world, and has become the largest buyer of liquid hydrogen, having built and operated a hydrogen highway across North America. Plug Power delivers a significant value proposition to end-customers, including meaningful environmental benefits, efficiency gains, fast fueling, and lower operational costs. Plug Power's vertically integrated GenKey solution ties together all critical elements to power, fuel, and provide service to customers such as Amazon, BMW, The Southern Company, Carrefour, and Walmart. The Company is now leveraging its know-how, modular product architecture and foundational customers to rapidly expand into other key markets including zero-emission on-road vehicles, robotics, and data centers.

SOURCE: PLUG POWER

Plug Media Contact
Kristin Monroe
Allison+Partners
[email protected]



These press releases may also interest you

at 03:30
New Electric Mountain Bike Player Amflow Enters Market, unveiling its Revolutionary First Bike powered by DJI Avinox at Eurobike 2024
Amflow, the eMTB expert that builds e-bikes from heart to body, today marks its entry into the industry with the launch of the Amflow PL. Providing a significantly robust 850 W of peak power and weighing in at an industry leading level of ultra-light...

at 03:17
Daniels Manufacturing Corporation Acquires MCD-Tools GmbH
Daniels Manufacturing Corporation® (DMC®) is proud to announce the successful acquisition of MCD-Tools GmbH, a leading tool distribution and repair company based near Frankfurt, Germany. DMC's acquisition of MCD-Tools allows DMC to form DMC Europe...

at 03:05
NIQ Activate Platform Now Available on Microsoft Azure Marketplace
NielsenIQ (NIQ) today announced the availability of NIQ Activate in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. NIQ customers can now take advantage of the productive and trusted Azure cloud...

at 03:05
Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships...

at 03:05
Manhattan Associates Celebrates Best Sustainability Initiative Win at the 2024 EMEA VIP Awards
Manhattan Associates today announced that it has been named winner of the VIP Awards' Best Sustainability Initiative category for 2024. Selected from a competitive group of nominees, Manhattan Active® Supply Chain technology was chosen because of...

at 03:05
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage...

More news about Science and technology...


News published on and distributed by: